Eli Lilly and Company $LLY Shares Sold by Elm3 Financial Group LLC

Elm3 Financial Group LLC reduced its position in shares of Eli Lilly and Company (NYSE:LLY) by 17.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,898 shares of the company’s stock after selling 1,016 shares during the period. Eli Lilly and Company accounts for about 3.1% of Elm3 Financial Group LLC’s investment portfolio, making the stock its 8th largest position. Elm3 Financial Group LLC’s holdings in Eli Lilly and Company were worth $3,737,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Lazard Freres Gestion S.A.S. raised its position in shares of Eli Lilly and Company by 114.3% in the 2nd quarter. Lazard Freres Gestion S.A.S. now owns 77,295 shares of the company’s stock valued at $60,253,000 after purchasing an additional 41,222 shares in the last quarter. Precedent Wealth Partners LLC grew its position in shares of Eli Lilly and Company by 15.3% during the second quarter. Precedent Wealth Partners LLC now owns 294 shares of the company’s stock worth $229,000 after buying an additional 39 shares in the last quarter. Central Pacific Bank Trust Division increased its stake in shares of Eli Lilly and Company by 25.8% in the third quarter. Central Pacific Bank Trust Division now owns 8,990 shares of the company’s stock worth $6,859,000 after buying an additional 1,843 shares during the last quarter. Capital Advisors Inc. OK raised its holdings in Eli Lilly and Company by 6.8% in the second quarter. Capital Advisors Inc. OK now owns 6,747 shares of the company’s stock valued at $5,260,000 after acquiring an additional 429 shares in the last quarter. Finally, Family CFO Inc bought a new position in Eli Lilly and Company during the 2nd quarter valued at $54,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Up 0.5%

Shares of Eli Lilly and Company stock opened at $1,079.83 on Monday. The company has a current ratio of 1.55, a quick ratio of 1.24 and a debt-to-equity ratio of 1.71. The business’s 50 day simple moving average is $1,013.16 and its 200-day simple moving average is $851.29. The stock has a market capitalization of $1.02 trillion, a price-to-earnings ratio of 52.83, a PEG ratio of 0.78 and a beta of 0.35. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,111.99.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.42 by $0.60. The business had revenue of $17.60 billion for the quarter, compared to the consensus estimate of $16.09 billion. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The business’s revenue was up 53.9% on a year-over-year basis. During the same quarter last year, the business posted $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Equities research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date of this dividend is Friday, February 13th. Eli Lilly and Company’s dividend payout ratio is presently 33.86%.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on LLY. Guggenheim reissued a “buy” rating and issued a $1,163.00 target price on shares of Eli Lilly and Company in a research report on Wednesday, December 3rd. Deutsche Bank Aktiengesellschaft boosted their price objective on Eli Lilly and Company from $1,000.00 to $1,200.00 and gave the company a “buy” rating in a report on Wednesday, December 17th. The Goldman Sachs Group increased their target price on Eli Lilly and Company from $951.00 to $1,145.00 and gave the stock a “buy” rating in a report on Monday, December 15th. UBS Group reiterated a “neutral” rating on shares of Eli Lilly and Company in a report on Thursday, December 18th. Finally, Wolfe Research upped their price target on Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the company an “outperform” rating in a research report on Wednesday, December 3rd. Five equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $1,155.36.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.